PERJETA + Herceptin + docetaxel nearly doubled pCR rates vs Herceptin-- NeoSphere

[Lani]

TDM1 is NOT cheno-free--the chemo it contains ( a maytansinoid) is an agent so toxic it cannot be used unless tethered to something which targets it only to the relevant cells(the herceptin it is linked to) and tethered to that so strongly in a way that it is only released when it gets inside the cell (Trojan horse-style).

I have posted both these results before while I attended ASCO in May/June, but reposted as genentech seems to be targeting prescribers (recently) with the info in the article ie, making it seem some other news might be upcoming shortly.

The aarticle applies to ER+ and ER- tumor pCR rates, whereas the second article is unique to er+HER2+ tumors, a subsubgroup which until now did not have any different treatment recommendations based on trial results than er-her2-

The treatment recommendations still have not changed as these are only reported trials, not treatment recommendations which is why Genentech's recent announcement to prescribers seemed so strange(will it prove timely???)